Cite
Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions.
MLA
Dong, Zhenyuan, et al. “Antitumor Efficacy of BAFF-R Targeting CAR T Cells Manufactured under Clinic-Ready Conditions.” Cancer Immunology, Immunotherapy, vol. 69, no. 10, Oct. 2020, pp. 2139–45. EBSCOhost, https://doi.org/10.1007/s00262-020-02614-8.
APA
Dong, Z., Cheng, W. A., Smith, D. L., Huang, B., Zhang, T., Chang, W.-C., Wang, X., Forman, S. J., Kwak, L. W., & Qin, H. (2020). Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions. Cancer Immunology, Immunotherapy, 69(10), 2139–2145. https://doi.org/10.1007/s00262-020-02614-8
Chicago
Dong, Zhenyuan, Wesley A. Cheng, D. Lynne Smith, Brian Huang, Tiantian Zhang, Wen-Chung Chang, Xiuli Wang, Stephen J. Forman, Larry W. Kwak, and Hong Qin. 2020. “Antitumor Efficacy of BAFF-R Targeting CAR T Cells Manufactured under Clinic-Ready Conditions.” Cancer Immunology, Immunotherapy 69 (10): 2139–45. doi:10.1007/s00262-020-02614-8.